Clarify the product, evidence, regulatory, development and commercial critical path.
Contact Genvissa
Bring us the decision that matters.
Tell us what you are trying to decide, de-risk or deliver. A useful first conversation starts with the outcome, not a long brief.
A useful first message
Three things help us get to the point quickly.
-
01
What are you building?
A concise description of the technology, intended user, setting and problem it is meant to solve.
-
02
What decision or outcome matters now?
For example, product definition, evidence, funding readiness, recovery, market entry or executive leadership.
-
03
Why now?
The milestone, risk, deadline or consequence that makes this important, plus any material constraints on time or budget.
Common reasons to get in touch
When complexity needs a clear owner.
Align the use of funds, programme plan and investment milestone with the evidence investors will scrutinise.
Identify root causes, contain immediate risk and build a credible recovery plan.
Define a fractional executive remit with clear accountabilities, boundaries and decision authority.
Reframe the proposition around pathway, evidence, economics, procurement and the people who must change behaviour.
Test the technical and operating reality behind the narrative and identify the value-creation priorities.
Start with a short email.
We will respond directly and establish whether Genvissa is the right fit before anyone invests time in a lengthy process.
A few practical points
Clear from the outset.
What types of medical technology do you support?
Genvissa works across the medical-device spectrum, from diagnostics and connected devices to therapeutic systems and implantable technologies. We assemble the right product, clinical, regulatory, engineering and commercial expertise around each challenge.
How early is too early?
Early is useful when there is a material decision to make. Pre-spinout and startup work is tightly scoped so scarce cash is used on the highest-value questions.
Where do you work?
Genvissa is based in the United Kingdom and can support UK and international work where the scope, market and required specialist competence are clear.